Active ingredient in ecstasy may help veterans with PTSD, study finds

MDMA -- the active ingredient in the banned street drug ecstasy -- is safe and enhances the treatment of post-trauma...

Posted: May 3, 2018 2:26 PM
Updated: May 3, 2018 2:26 PM

MDMA -- the active ingredient in the banned street drug ecstasy -- is safe and enhances the treatment of post-traumatic stress disorder when administered during psychotherapy, according to a new clinical trial.

More research is needed to fully assess the drug, caution the authors of the US Food and Drug Administration-approved experiment. The study included just 26 patients, all of them veterans, firefighters and police officers who developed PTSD as a result of trauma in the line of duty.

Effects of psychotherapy and sessions of MDMA-assisted psychotherapy were studied

One year later, 67% of all participants no longer qualified for a diagnosis of PTSD

MDMA -- or 3,4-methylenedioxymethamphetamine -- has been illegal in the United States since 1985.

"MDMA has some stimulant effects as well as psychoactive effects," said Dr. Michael C. Mithoefer, lead author of the study and a psychiatrist in the department of psychiatry and behavioral sciences at the Medical University of South Carolina.

The drug is sometimes described as an "empathogen" or "entactogen," he added, because it "rarely causes hallucinations or disorientation and tends to increase feelings of empathy and trust and increased awareness of inner experience."

"We obtained FDA approval for our first clinical trial in 2001," Mithoefer said. "We began our first phase two clinical trial here in Charleston in 2004 treating mostly crime-related PTSD such as childhood abuse or rape in individuals who had failed to respond to psychotherapy and medications."

Promising results from previous trials led to the new study, published Tuesday in the journal The Lancet Psychiatry, he said.

Search for new therapies

PTSD, a disorder that develops in some people who have experienced a shocking or dangerous event, affects about 8 million American in any given year.

Continuing symptoms, including flashbacks and frightening thoughts, may lead to substance abuse, unemployment, family disruption and even suicide. Existing treatments for PTSD include various forms of psychotherapy, such as exposure therapy and cognitive processing therapy, and/or prescription drugs, such as antidepressants.

Up to 72% of veterans who receive psychotherapy retain their PTSD diagnosis and frequently drop out of their treatment programs, according to a previous unrelated study.

The need for improved PTSD therapies is clear, Mithoefer and his co-authors say, adding that the "development of new treatments should address the common reasons for treatment avoidance, failure, and dropout."

The Multidisciplinary Association for Psychedelic Studies, a nonprofit research organization, funded Mithoefer's study of 22 veterans, three firefighters and one police officer, all with service-related PTSD lasting longer than six months.

"We only included people who had received prior treatment but still had clinically significant PTSD," Mithoefer said of the study, which followed the FDA's strict guidelines for a phase two trial.

All 26 participants received a course of treatment that consisted of about 13 hours of non-drug psychotherapy plus two eight-hour sessions of MDMA-assisted psychotherapy. Participants were randomly assigned to receive MDMA (orally) in one dose of either 30, 75 or 125 milligrams for each of the two MDMA-assisted psychotherapy sessions.

One month after the second MDMA session, 68% of patients in the two higher-dose groups no longer qualified for a diagnosis of PTSD, while the same was true of 29% of patients in the lowest-dose group. One year later, 67% of all participants no longer qualified for a diagnosis of PTSD, the study results indicate. Those participants who still met the criteria for PTSD experienced a reduction in symptoms, the researchers noted.

Experts disagree on findings

The most frequently reported immediate side effects of MDMA were anxiety, headache, fatigue and muscle tension. One week after treatment, some participants experienced anxiety, fatigue and insomnia. Four serious side effects were reported during the course of the study, though three of these events -- suicide ideation, major depression and appendicitis -- were not attributed to MDMA.

One participant experienced premature ventricular contractions -- extra beats in one chamber of the heart -- at the outset of the study and during the study. After an overnight stay in a hospital, the patient recovered fully, the researchers reported.

Dr. Neil Greenberg, a professor of defence mental health at King's College London, said the study may be "interesting" but does not "fundamentally change" the services offered for PTSD treatment.

Greenberg, who was not involved in the study, noted that 22 of the 26 participants had been recruited from the internet, "and one has to assume they were interested in taking a psychedelic drug." He also said that some of the participants received prior treatments that were either not evidence-based or known to be effective with PTSD; a sample "bias" such as this weakens the quality of any analysis.

Overall, he said, future research of the effects of MDMA on patients with PTSD might be watched with interest, but he does not recommend any stronger actions, "given the controversial nature of the medication, the risk of serious side effects and the small and biased sample" of participants.

But David Nutt, a professor of neuropsychopharmacology at Imperial College London, said the new study is "the biggest breakthrough in medicinal PTSD treatment for two decades" and "opens a potential new era in the treatment of PTSD."

According to Nutt, who was not involved in the study, the results suggest that "MDMA should be fast-tracked to clinical acceptance" since the evidence is now sufficient to warrant its wider use in treating PTSD.

In his own research, Nutt explored the neurological effects of MDMA in healthy participants. His work showed that MDMA "reduces fear responses, which probably explains how it works to aid psychotherapy in PTSD," he said.

Nutt will be conducting a study of MDMA in alcoholics who drink in an attempt to deal with prior trauma.

Not a 'daily drug'

MDMA was first synthesized in 1912 by a German pharmaceutical company that intended to use it as a blood clotting agent. In the 1970s, a small number of psychotherapists made use of it in couples' therapy, where it was shown to help traumatized clients address repressed emotional memories "without being overwhelmed by the negative affect that usually accompanies such memories," Nutt wrote in a report. In the 1980s, MDMA lost its legal status around the world under a United Nations agreement, having fallen into disrepute as a street drug.

However, some scientists remained convinced of its potential and persisted in their research. In the early 1990s, the FDA approved experiments in which MDMA was used as an adjunct to psychotherapy. Ongoing research in a similar vein resulted in the new study, among others, in addition to the FDA agreeing in 2017 to expedite its review of MDMA-assisted psychotherapy for PTSD.

Phase three clinical trials of MDMA-assisted psychotherapy for PTSD, involving 200 to 300 participants across 16 sites in the United States, Canada and Israel, will begin in the summer, according to Mithoefer. If these trials demonstrate sufficient efficacy and an acceptable safety profile, FDA approval of the treatment is expected by 2021.

"Unlike most other drug studies, MDMA is not being used as a daily drug," Mithoefer said. Using the drug as a catalyst to psychotherapy means it is used only a few times, at monthly intervals, which is appealing to psychiatrists, he noted. "Taking it only a few times decreases side effects compared to daily dosing," he said, and it "eliminates the possibility of abuse, since it is administered directly by the therapists."

"If it is approved by FDA for clinical use, it will likely be restricted to specialized clinics with properly trained therapists, not as a take-home medicine that people get from the pharmacy," Mithoefer said.

Indiana Coronavirus Cases

Data is updated nightly.

Cases: 1101185

Reported Deaths: 17557
CountyCasesDeaths
Marion1441632231
Lake715041238
Allen65802880
Hamilton50322484
St. Joseph48966643
Elkhart39621543
Vanderburgh34317495
Tippecanoe30336273
Johnson27293465
Hendricks25947380
Porter25171386
Madison20749447
Clark19985277
Vigo18838308
LaPorte16924261
Delaware16480297
Howard16432311
Monroe16415219
Kosciusko13976165
Hancock12899185
Bartholomew12729189
Warrick12051190
Wayne11921267
Floyd11901226
Grant11755240
Morgan10276190
Boone9706121
Noble9094122
Henry9040165
Marshall8932147
Dearborn8866100
Dubois8751139
Shelby8101129
Cass8055127
Lawrence7939184
DeKalb7638107
Jackson752693
Huntington7475110
Gibson7019118
Montgomery6930123
Harrison688298
Knox6855115
Steuben655787
Miami6497109
Whitley644860
Putnam635583
Clinton619877
Wabash6080109
Jasper604992
Jefferson5710103
Ripley550292
Adams533781
Daviess5020117
Scott482880
Wells4733101
White470368
Greene463899
Clay459762
Decatur4548110
Jennings441766
Fayette438494
LaGrange421290
Posey404044
Washington385455
Randolph3834107
Fountain368762
Spencer357347
Fulton356872
Starke349073
Owen347577
Sullivan345754
Orange325571
Jay321950
Rush299632
Carroll290238
Franklin287144
Perry285153
Vermillion281158
Tipton248265
Parke247030
Pike245044
Blackford218744
Pulaski206458
Newton179752
Brown174050
Crawford168129
Benton163917
Martin151719
Switzerland145612
Warren132316
Union118316
Ohio91813
Unassigned0587

Ohio Coronavirus Cases

Data is updated nightly.

Cases: 1690217

Reported Deaths: 26587
CountyCasesDeaths
Franklin1772171827
Cuyahoga1648472640
Hamilton1125391528
Montgomery796451395
Summit705111199
Lucas620241020
Butler56096805
Stark527941171
Lorain41276642
Warren35509412
Mahoning35270771
Lake31622495
Clermont30804363
Delaware26791182
Trumbull26782616
Licking26297336
Medina25419351
Fairfield24256287
Greene24097372
Clark21748387
Portage20807281
Richland20686340
Wood19745246
Allen18638320
Miami17074348
Columbiana16571332
Muskingum16483206
Wayne15482306
Tuscarawas14158360
Marion13116194
Erie12479198
Ashtabula12417232
Scioto12288184
Pickaway12114153
Ross11526225
Hancock11321173
Geauga10726175
Lawrence10531172
Belmont10304234
Huron9633158
Jefferson9504227
Union944075
Sandusky9106166
Seneca8752157
Knox8663170
Washington8632158
Athens828996
Darke8288180
Ashland7873149
Auglaize7794117
Shelby7369133
Defiance7243115
Crawford7129150
Brown7072115
Fulton7058112
Logan6899108
Guernsey684284
Mercer683998
Highland6659119
Madison643889
Clinton6422106
Williams635899
Preble6194140
Putnam6126120
Jackson574096
Champaign570687
Perry561179
Coshocton5576104
Ottawa555499
Morrow509364
Fayette485370
Hardin480699
Gallia465478
Pike460176
Van Wert458993
Adams4531109
Henry426978
Hocking403093
Holmes3947140
Wyandot369373
Carroll354478
Paulding320551
Meigs303459
Monroe233661
Noble218047
Morgan212138
Harrison206953
Vinton184337
Unassigned06
Fort Wayne
Partly Cloudy
46° wxIcon
Hi: 47° Lo: 28°
Feels Like: 40°
Angola
Partly Cloudy
46° wxIcon
Hi: 46° Lo: 29°
Feels Like: 40°
Huntington
Partly Cloudy
44° wxIcon
Hi: 47° Lo: 27°
Feels Like: 39°
Decatur
Partly Cloudy
46° wxIcon
Hi: 46° Lo: 27°
Feels Like: 40°
Van Wert
Partly Cloudy
48° wxIcon
Hi: 47° Lo: 27°
Feels Like: 42°
The warming trend is expected to continue through Thursday, before cooler air returns to the Midwest for the weekend.
WFFT Radar
WFFT Temperatures
WFFT National

Community Events